# Characterization of products synthesised in the interaction of 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol with piperidine or morpholine

Albertas Rutavičius\*, Zenonas Kuodis, Algirdas Matijoška and Laimutė Rastenytė

Goštauto 9, LT-2600 Vilnius, Lithuania E-mail: algula@takas.lt

Institute of Chemistry,

Synthesis and characterization of piperidine or morpholine 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol were explored influences of the ratio of reactants on the course of the reaction were determined.

**Key words**: 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol; quaternary salts; *Mycobacte-rium tuberculosis* 

## INTRODUCTION

1,3-benzoxazole-2-thiol is known to form 2-amino-substituted oxazoles upon heating with a surplus of morpholine or piperidine [1]. 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol heated with an equivalent amount of morpholine or piperidine in dimethylformamide as a solvent undergoes a cleavage of oxazole ring and the corresponding N'-(1-carbothioyl)isonicotino-hydrazide is formed [2]. Also, it has been established that in the presence of double surplus of morpholine N'-(4-morpholinylcarbothioyl)isonicotino-hydrazide and (in the presence of double surplus of piperidine) piperidinium 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiolate are formed.

# RESULTS AND DISCUSSION

In the current study, the interaction of 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol with secondary amines (piperidine and morpholine) was explored. Independently of the ratio of the reaction agents the same products were obtained; the identity of those was confirmed by elemental analysis and melting point data measurement.

Analysis of the IR and the NMR <sup>1</sup>H data revealed the formation of the corresponding 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiolate salts **1a** and **1b**. Thus, the possibility of the formation of the corresponding thiosemicarbazide is excluded by the ab-

sence of the absorption bonds at  $1680-1670 \text{ cm}^{-1}$  (ascribed to C = O group) as well as at 1520 and  $1320 \text{ cm}^{-1}$  (ascribed to C = S group) in the IR spectra and thera are no signals of C(S)NH (at 7.8-8.8 ppm) and C(O)NHNH (at 9.2-10.4 ppm) groups in the data of NMR  $^{1}$ H spectra of compounds 1a and 1b. Finally, the quaternary salt structures of 1a and 1b were confirmed by the mass-spectra data.

The primary screening showed compounds 1a, b exhibited an effective tuberculosis antimicrobical acquisition and the concentration of 6.25 mg/ml, exerted a >90% inhibition of the Mycobacterium tuberculosis strain  $H_{37}RV$  (ATCC 27294). The investigation were performed within the programme "Tuberculosis Antimicrobical Acquisition Coordination Faculty (TAACE)" through a research and development contract with the US National Institute of Allergy and Infectious Diseases.

# **EXPERIMENTAL**

NMR <sup>1</sup>H spectra were recorded on a Tesla BS-567A NMR spectrometer at 80 MHz with TMS as the internal standard. IR spectra were recorded on a UR-10 in KBr spectrometer. Mass-spectra were mea-

<sup>\*</sup> Coresponding author.

sured on an AMD 604 (AMD Interco GmbH) using electron ionisation (E1, 70 eV).

Synthesis of piperidinium 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiolate (1a). 5.38 g (30 mmol) of 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol [3], 2.55 g (30 mmol) of piperidine were added to 20 cm<sup>3</sup> of anhydrous dimethyl sulfoxide (DMSO) and the reaction mixture was heated for 10 h at 60 °C. Then DMSO was partially evaporated (till the first crystals appeared), diluted with benzene and the formed crystals were filtered off and washed with 2-propanol. Obtained: 4.1 g (51%) of 1, mp 74–75 °C,  $\delta_{H}$  (p pm) in (CD<sub>3</sub>)<sub>2</sub>SO: 1.68 (6H, m, 3CH<sub>2</sub>), 3.08 (4H, m, CH<sub>2</sub>NCH<sub>2</sub>), 7.76 (2H, d, J = 6.0, 3-H, 5-H), 8.77 (2H, d, J = 6.0, 2-H)H, 6-H). MS, m/z (% rel. int.): 264 (0.2) M+; 181 (5); 179 (100) [oxazol 1]+; 119 (9); 92 (20); [C<sub>s</sub>H<sub>11</sub>N]+; 84 (37)  $[C_5H_{11}N-1]^+$ ; 78 (6)  $[C_6H_5N-1]^+$ ; 57 (13); 43 (8); 41 (15). Found: C, 54.52; H, 6.05; N, 21.25. C<sub>12</sub>H<sub>16</sub>N<sub>4</sub>OS requires: C, 54.52; H, 6.09; N, 21.20%).

Synthesis of morpholine-4-ium 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiolate (1b). The preparation of 2b was carried out as described for 1a. From 2.69 g (15 mmol) of 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol 1.3 g (15 mol) of morpholine to 10 cm³ of anhydrous DMSO was obtained: 2.1 g (55%) of 2, mp 166–167 °C,  $\delta_{\rm H}$  (p pm) in (CD<sub>3</sub>)<sub>2</sub>SO: 3.15 (4H, m, CH<sub>2</sub>NCH<sub>2</sub>), 3.79 (4H, m, CH<sub>2</sub>OCH<sub>2</sub>), 7.76 (2H, d, J = 6.0, 3–H, 5–H), 8.65 (2H, d, J = 6.0, 2–H, 6–H). MS, m/z (% rel. int.) : 267 (4) [M+1]; 266 (2) [M+]; 239 (5); 225 (5); 211 (6); 183 (7); 179 (10), [oxazol]+; 141 (10); 113 (15); 87 (36) [C<sub>4</sub>H<sub>9</sub>NO]+; 86 (20) [C<sub>4</sub>H<sub>9</sub>NO-1]+; 57 (100); 43 (40); 41 (16). Found: C, 49.70; H, 5.26; N, 21.11. C<sub>11</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S requires: C, 49.61; H, 6.09; N, 21.04%.

### **CONCLUSIONS**

- 1. Piperidine or morpholine with 5-(4-pyridinyl)-1,3,4-oxadiazole-2-thiol when heated at 60 °C in DMSO formed quaternary salts.
- 2. The quaternary salts showed a >90% inhibition in primary screening against the *Mycobacterium tuberculosis* strain  $H_{27}RV$ .

Received 6 October 2003 Accepted 27 October 2003

### References

- K. Davidkov and D. Simov, *Dokl. Bolg. AN*, 21, 1193 (1970).
- 2. V. Jakubkienė and P. Vainilavičius, *Khim. Heterotsikl. Soed*, **8**, 1125 (1998).
- 3. A. Rutavičius and Z. Kuodis, *Khim. Heterotsikl. Soed*, **2**, 961 (2002).

## A. Rutavičius, Z. Kuodis, A. Matijoška, L. Rastenytė

JUNGINIŲ, GAUTŲ SĄVEIKAUJANT 5-(4-PIRIDINIL)-1,3,4-OKSADIAZOL-2-TIOLIUI SU PIPERIDINU ARBA MORFOLINU, IDENTIFIKACIJA

Santrauka

Nustatyta, kad sąveikaujant 5-(4-piridinil)-1,3,4-oksadiazol-2-tioliui su piperidinu arba morfolinu oksadiazolo žiedas neskyla, o susidaro atitinkamos ketvirtinės amonio druskos. Pirminiai gautų junginių farmakologinio aktyvumo nustatymo tyrimai parodė didelį prieštuberkuliozinį aktyvumą (94–96%) *Mycobacterium tuberculosis* H<sub>37</sub>RV atžvilgiu (ATCCC27294).